NR1H4 and metabolic dysfunction-associated steatohepatitis: ,14 The first-in-class selective FXR agonist obeticholic acid (OCA; INT-747 [6a-ethyl-chenodeoxycholic acid]) improved fibrosis by ≥1 stage (with no worsening of NASH) in 22.4% of patients in the high-dose arm (vs. 9.6% receiving placebo; p < 0.0001) in the REGENERATE phase III clinical trial (ClinicalTrials.gov Identifier: NCT02548351).13